Question-and-Answer Session
Operator
(Operator Instructions) And we will go first to Annabel Samimy - UBS.
Annabel Samimy - UBS
On the Sular, have you started drawing down inventories before January? It seems like the cardiovascular was a little bit lighter than we would have expected. Have there been any major changes in inventories or changes in rebating for the fourth quarter?
Darrell Borne
Yes, we actually did have lower sales in the fourth quarter versus the third quarter Sular sales. You are right, that was by design getting obviously ready for the launch in the first quarter.
Annabel Samimy - UBS
And you mentioned that you had some pre-marketing activity for Sular. What kind of a feedback have you started getting from some of the sales reps after the launch who has these pre-marketing activities going on?
Edward Schutter
It’s actually been good feedback. We’ve had a pre-launch campaign going on for several weeks now where we’ve been into pharmacies and physicians, particularly in the physicians’ offices focusing on the retail nurses. So if and when they get a call to convert the prescription that they will be totally aware of the new product coming in.
Feedback has been very positive. We’ve also been working obviously in other ways with chain headquarters and the mail services accounts as well to make sure that they help us communicate the message of new Sular.
Annabel Samimy - UBS
On a pipeline question for CloniBID, can you give us a sense of whether there is any measure of sedation with CloniBID in a Phase III I know is a PK study? But I guess your whole point is you’re trying to match the PK of Catapres patch, and it seems in the label that the Catapres patch refers to the same types of side effects, sedation and drowsiness as the oral quantity. And so could you help us understand how you’re going to differentiate CloniBID aside from just PK?
Larry M. Dillaha, M.D.
They actually did measure sedation in trial. It was a little more than just a PK study, they actually had patients in there. I don’t think we even have enough numbers yet, but they had very good results in relation to sedation. So, I think we’re very happy with the results as they stand.
Annabel Samimy - UBS
With the five of five being cured, are you going to be able to find a way to put that in a label or is it primarily going to be on marketing?
- To read the full transcript on Seeking Alpha, click here »
